阿斯利康股票討論區

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$美國聯合醫療(UTHR.US)$  Phase 3
$美國聯合醫療(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$烏龍製藥(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$傳奇生物(LEGN.US)$ & $強生(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$阿斯利康(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $施貴寶(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$萬達生物製藥(VNDA.US)$...

🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$默沙東(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$阿斯利康(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$再生元製藥公司(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$阿斯利康(AZN.US)$ : 🤔
⇒...

$SPDR標普生物科技ETF(XBI.US)$
$默沙東(MRK.US)$ x $Immunovant(IMVT.US)$
$禮來(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元製藥公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科學(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施貴寶(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$禮來(LLY.US)$ x $Merus(MRUS.US)$ (partner n...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$和黃醫藥(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$烏龍製藥(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

$阿斯利康(AZN.US)$ Ultomiris now approved for Tx of
neuromyelitis optica spectrum disorder (NMOSD)
⇒ sBLA approved as 4th indication 👏
⇒ 1st and only long-acting C5 complement inhibitor,
offers Px with AQP4 Ab+
⇒ CHAMPION-NMOSD trial - met primary endpoint 🔬
⇒ Ultomiris (ravulizumab-cwvz) inj., for IV use 💉

RECAP
Stocks closed higher Tuesday, ramping up from a morning pullback as the market reacted to the news that $英偉達(NVDA.US)$ announced a large computer chip for AI processing at its GTC event Monday night. Investors await the FOMC policy statement on Wednesday, where the market has priced in a 99% chance of no rate change.
With preliminary numbers, the $標普500指數(.SPX.US)$ climbed 0.56% to its 18th record close of the year at ...